Beijing Senmiao Biological Technology

Beijing Senmiao Biological Technology, also known as Senmiao Biotechnology and formerly Beijing Yufan Biotechnology, is a Beijing-based biotechnology company focused on developing innovative immune-modulation therapies and vaccines. Founded in 2020, the company leverages its expertise in TLR7/8 agonists, HPK1 (Hematopoietic progenitor kinase 1) inhibition, and antibody-drug conjugates (ADCs) to target unmet needs in oncology and infectious diseases. Senmiao's research is supported by strong academic ties, particularly with Tsinghua University, and it has secured significant venture capital from investors like Lapam Capital. The company is currently in the advanced preclinical stage, advancing a pipeline of targeted immunotherapies and vaccine adjuvants while strategically investing in related pharmaceutical ventures.